Vietnam Blames Deputy Minister, DAV For Broader Vaccine Approval
This article was originally published in PharmAsia News
Vietnam authorities blame a deputy minister of health and the nation's drug agency for allowing wider use of a pair of cervical cancer vaccines than generally permitted. An inspector for the Ministry of Health was ordered to look into the issue after Merck Sharp and Dohme, and GlaxoSmithKline were accused of improper lobbying to get the broader-use recommendation. The inspector said the deputy minister and the Drug Administration of Vietnam were responsible for approving Merck's Gardasil and GSK's Cervarix for women as old as 55 instead of the normal age span of 10 to 25. The deputy and DAV leaders ordered two medical councils involved to reconsider the age of users, the inspector said. (Click here for more
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.